Waldenstrom’s Macroglobulinemia

What is it?

Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell, which normally matures into a plasma cell whose job is to manufacture immunoglobulins (antibodies) to help the body fight infection. In WM, there is a malignant change to the B-cell in the late stages of maturing, and it continues to proliferate into a clone of identical cells, primarily in the bone marrow but also in the lymph nodes and other tissues and organs of the lymphatic system. These clonal cells over-produce an antibody of a specific class called IgM.

Under the microscope, WM cells have characteristics of both B-lymphocytes and plasma cells, and they are called lymphoplasmacytic cells. For that reason, WM is classified as a type of non-Hodgkin’s lymphoma called lymphoplasmacytic lymphoma (LPL). About 95% of LPL cases are WM, but it is a very rare disease – only about 1,500 patients are diagnosed with WM each year in the US. WM is usually indolent (slow growing) and can be managed as a chronic disease for a number of years. However, it is not yet curable.

As a result of proliferation in the bone marrow and other sites, the lymphoplasmacytic cells of WM may interfere with normal functioning. In the bone marrow where blood cells are produced, the WM cells “crowd out” the normal blood cells and may lead to a reduction in normal blood counts; in the lymph nodes and other organs, the WM cells may lead to enlargement of these structures and other complications.

The over-production of IgM may also cause many of the symptoms associated with the disease. IgM is a large antibody and tends to make the blood thicker than normal, a condition called hyperviscosity. Unlike normal antibodies that fight infection, the IgM produced by WM cells has no useful function. Sometimes the IgM may incorrectly recognize the body’s tissues as “foreign” and attach to them, causing inflammation and injury.

Waldenstrom’s macroglobulinemia is named for the Swedish physician Jan Gosta Waldenström (1906-1996), who in 1944 identified a rare condition in which two patients experienced a thickening of their blood serum, bleeding of the mouth, nose, and blood vessels of the retina, low red blood cell and platelet counts, high erythrocyte sedimentation rates, and lymph node involvement. Bone marrow biopsies showed an excess of lymphoid cells and bone X-rays were normal, excluding a diagnosis of multiple myeloma. Both patients also had a large amount of a single unknown blood protein with an extremely high molecular weight, a “macro” globulin. We now know this globulin as IgM.

Causes and risk factors

There is no definitely known cause of WM. As is the case with most cancers, there are probably multiple risk factors involved – some may be inherited predisposing genetic factors and some may be due to environmental or occupational exposures acquired during one’s lifetime.
There are several known risk factors that increase the chance of developing WM. These include the following:

- **Male sex** – The incidence of WM is significantly greater in men than in women.
- **Increasing age** – The median age at diagnosis is approximately 65 years, although patients as young as 18 have been reported. The annual incidence increases dramatically as age increases.
- **Caucasian race** – The incidence is higher in whites than in blacks, but reliable figures for other races are not available.
- **IgM monoclonal gammopathy of undetermined significance (IgM MGUS)** – This refers to a condition in which the presence of a monoclonal IgM has been detected from blood tests, but there is no evidence of malignancy. In one long-term study of IgM MGUS, the incidence of progression to WM and other B-cell malignancies was 10% at 5 years, 18% at 10 years, and 24% at 15 years – a progression rate of approximately 1.5% each year.

Several studies report an element of familial susceptibility, as approximately 20% of patients have family members with WM or other B-cell malignancies.

Environmental factors such as radiation exposure, Agent Orange exposure, and occupational exposure to leather, rubber, paints, dyes, and solvents have also been implicated in some studies, as have certain autoimmune diseases and viruses such as hepatitis C. However, none of these environmental factors has consistently been determined to increase risk.

**Prognosis**

There are no treatments that can cure WM, although in most cases the disease is slow growing and can be effectively managed with appropriate therapies.

Much of the older literature on WM quotes a survival rate of 5-7 years after diagnosis, and this number still shows up from time to time. Patients should be aware that this was based on studies conducted before many of the newer treatments, especially monoclonal antibodies and proteasome inhibitors, were widely used. Noted WM researchers are suggesting that survival is much better today given the rapid improvements in therapeutic options for WM patients.

**Signs and symptoms of disease**

Because WM is slow growing, there may be no signs or symptoms of disease for years before and even after diagnosis. Because there are currently no treatments that cure WM or that halt its progression, patients who are asymptomatic or who have mild symptoms should be placed on “watch and wait,” a period during which they are not treated but instead are regularly monitored by a hematologist-oncologist for changes in their disease status.
When signs or symptoms do occur, there may be no correlation between the level of monoclonal IgM and/or the amount of bone marrow infiltration with the degree of symptom severity. Patients with similar laboratory test results can have markedly different types and degrees of symptoms.

The following are conditions along with typical signs or symptoms that can occur in WM patients – depending on their severity, they may indicate the need for treatment. It is important to note that several of these signs and symptoms are also associated with other conditions, and one should not necessarily assume that WM is the only cause.

**Anemia** – decreased production of red blood cells, which carry oxygen from the lungs to the tissues. Although anemia has many causes, it is the most common manifestation of lymphoplasmacytic cell infiltration in the bone marrow, and its symptoms often initiate the process leading to a WM diagnosis. These symptoms include pallor, weakness, fatigue, lightheadedness, palpitations of the heart, and shortness of breath.

**Lymphadenopathy, splenomegaly, and hepatomegaly** – enlargement of the lymph nodes, spleen, and liver, respectively. Unless the enlargement is significant, it is frequently not noticeable.

**Hyperviscosity** – increased thickness of the blood, which in WM is caused by a high IgM level. Signs and symptoms of hyperviscosity include chronic bleeding from the nose, gums, and less commonly, the gastrointestinal tract; headache; ringing in the ears; dizziness; loss of coordination or balance, impaired hearing; blurring or loss of vision; distended, sausage-shaped veins in the retina; and swelling of the optic disk at the back of the eye. In severe cases, heart failure, sleepiness, stupor, and coma can develop. Symptoms of hyperviscosity occur most commonly at IgM concentrations greater than 4,000 mg/dL. However, such concentrations are not necessarily associated with hyperviscosity, as there is considerable variability in the amount of IgM that produces hyperviscosity symptoms in an individual.

**Constitutional symptoms (also called B symptoms)** – these include recurring fever, night sweats, weight loss, and fatigue.

**Peripheral neuropathy** – characterized by numbness, tingling, burning, or prickling sensations that are commonly first noticed in the feet. The sensations are usually symmetrical, affecting both feet equally, and slowly progress to the knees before beginning to affect the hands and arms. Weakness of the legs and arms may develop. Peripheral neuropathy is seen in approximately 25% of WM patients and can occur because the monoclonal IgM targets specific components of the nerves, thereby affecting nerve conduction. It can also be caused by treatments that include bortezomib, thalidomide, or other neurotoxic agents.

**Cold agglutinin disease** – characterized by the presence of a high concentration of circulating antibody directed against the red blood cells. The antibody typically binds to the cells at low body temperatures and can cause hemolytic anemia (destruction of red blood cells). Signs and symptoms vary according to the severity of the disease and may include painful fingers and toes upon exposure to the cold, anemia, fatigue, shortness of breath, jaundice, Raynaud’s phenomenon (whiteness of the fingers, toes, nose, and/or ears) when cold, and dark urine caused by the presence of hemoglobin.
Cryoglobulinemia – a condition in which the circulating IgM has the properties of a cryoglobulin, which is a protein that precipitates at low body temperatures. When the IgM concentration reaches high levels, the precipitated antibody physically obstructs smaller blood vessels, leading to blueness of the fingers and toes when cold; Raynaud’s phenomenon; purpura (purple skin marks); and bleeding, ulcers, and gangrene of the fingers, toes, nose, and ears.

Thrombocytopenia – decreased production of platelets, which are important in blood clotting. Typical symptoms are bleeding, usually from the gums and nose, pinpoint flat red discolorations on the skin called petechiae, and easy bruising.

Amyloidosis – a group of rare diseases caused by the presence of an abnormal protein called amyloid in various tissues and organs of the body. The amyloid protein forms fibrils that may injure these body parts or interfere with their normal functioning. The protein may be deposited in a localized area or throughout the body. The most common tissues and organs involved are the kidneys, heart, gastrointestinal tract, peripheral nerves, and liver. Symptoms can vary widely based on which tissues and organs have the abnormal fibril deposits. Signs and symptoms of amyloidosis may be vague, such as weakness, fatigue, weight loss, shortness of breath, abnormal sensation in the feet, enlarged liver and/or spleen, bleeding under the skin, or anemia. More specific signs and symptoms might include swelling of the extremities, an enlarged tongue, carpal tunnel syndrome, food malabsorption, skin thickening, unexplained congestive heart failure, and unexplained kidney failure.

Bing-Neel syndrome – characterized by the infiltration of lymphoplasmacytic cells or IgM in the central nervous system (brain and spinal cord). This is a very rare condition which can result in mental deterioration, confusion, visual disturbances, irritability, personality changes, convulsions, and coma.

Other signs and symptoms – recurring infections, particularly of the sinuses and upper respiratory tract, may occur more often in WM patients than in the normal population. Occasionally the lymphoplasmacytic cells of WM will infiltrate the lung and produce masses or pleural effusion (fluid in the chest). Involvement of the kidneys and lesions in the bones are rare. Occasionally patients will have a rash or hives, and rarely the lymphoplasmacytic cells may infiltrate the skin. A small number of patients may exhibit masses of WM cells in various parts of the body, including the extremities, the spine, the breast, and the eye socket.

Common medical tests used for diagnosis and disease monitoring

The physical examination is the process by which a health care professional examines the body of a patient for signs of disease. It follows the taking of a medical history, which is an account of the symptoms experienced by the patient as well as questions regarding the patient’s current and past health history.
The frequency of physical examinations to monitor the disease after diagnosis depends on disease status. Patients with smoldering WM who are stable may not need to see a hematologist-oncologist more than once or twice a year. Newly diagnosed patients or those with progressing disease will be followed at more frequent intervals, perhaps once every 2-3 months. Patients in treatment may be monitored even more frequently (possibly even weekly) because of side effects that need to be recognized early to be effectively managed.

Various tests are performed to establish a WM diagnosis. Many of these same tests are used to monitor the status of the disease, before, during, and after treatment.

**Bone marrow biopsy** – The bone marrow biopsy (BMB) is the definitive test for confirming the diagnosis of WM. While necessary for diagnosis, it is infrequently used to monitor the disease. This procedure can be performed in a physician’s office or in a monitored setting (such as a hospital) under local anesthetic or light sedation. The specimen is usually obtained from the posterior iliac crest (back of the hip bone) by using a large-bore needle, although in some cases it may be taken from the sternum (breast bone) or other bones. Both a liquid bone marrow sample (bone marrow aspiration) and a solid bone sample (bone marrow biopsy) may be taken during the procedure.

A pathologist examines the bone marrow cells under a microscope and may also perform additional testing with special stains, flow cytometry, or FISH analysis to further identify the type of cancer cells present. In WM, the pathologist will note an increased amount of lymphoplasmacytic cells (which have features of both lymphocytes and plasma cells) and estimate the amount of infiltration of these cells into the bone marrow. He will also examine the marrow to determine how healthy it is and whether it appears capable of generating adequate amounts of normal blood cells.

Even with sedation, a patient may experience brief discomfort during the procedure and some soreness in the biopsy area afterwards when the numbing medicine wears off. Most patients can go home right after the procedure.

One of the primary means to assess a WM patient’s disease status is through periodic blood tests. Among the more common test sets are the Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), and Immunoglobulins. Other tests listed below may be added as needed.

**Complete Blood Count** – This panel measures the concentration of white blood cells, red blood cells, and platelets in the blood and provides other useful information about the structure of these cells. This test also determines the amount of hemoglobin in the blood. Hemoglobin is the molecule in red blood cells that is responsible for carrying oxygen throughout the body. In WM patients, the red cell count and hemoglobin may be lower than normal, leading to anemia. This is one of the most common conditions occurring in WM patients and frequently leads to the need for treatment.

**Comprehensive Metabolic Panel** – This test provides an overall picture of your body's chemical balance and metabolism. The panel measures the blood levels of albumin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, potassium, sodium, total bilirubin, total protein, and liver enzymes (alanine aminotransferase, alkaline phosphatase, and aspartate aminotransferase).
**Immunoglobulins** – These are antibodies (proteins) produced by the body to help fight infection. Immunoglobulin M (IgM) is over-produced by the WM cancer cells and is one of the most common markers used to diagnose and monitor the disease. The other immunoglobulins, such as IgG and IgA, are frequently lower than normal in WM patients, potentially leading to an increased risk of infections.

**Imaging Tests** – X-rays, CT scans, MRIs, ultrasounds, and PET scans may be useful in the diagnosis and monitoring of the disease, particularly if patients have enlarged lymph nodes or an enlarged spleen.

**Dilated eye examinations** – These are recommended for WM patients at least once a year and should be performed more frequently if a patient has blurring or loss of vision or if hyperviscosity (excessive thickening of the blood) is suspected. It is preferable to have an ophthalmologist who is knowledgeable about WM and its effects on the eye perform the examination.

**Treatments and side effects**

WM patients should be treated when they have symptoms and not on the basis of blood test results alone. This applies not only to consideration of initial (frontline) treatment but also to treatment following relapse, which is sometimes called salvage therapy. Many therapies have toxic side effects, and treating patients who don’t yet have symptoms may potentially have an adverse effect on quality of life and health.

Ibrutinib is approved for the treatment of Waldenstrom’s macroglobulinemia by the US Food and Drug Administration, the European Commission, and Health Canada. Prior to its approval, most treatments used for WM were approved for the related cancers of follicular lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Once Phase 1 and Phase 2 clinical trials established that these treatments had an acceptable safety profile and were effective for WM patients, they were prescribed for “off label” use in WM. The process of “off label” prescription is still in use today.

There is no single standard of therapy to treat WM. Many treatment options are available to WM patients, and a full discussion of each is beyond the scope of this fact sheet. Currently available treatment options may include one or more of the following:

- **Chemotherapy** with alkylating agents such as chlorambucil, cyclophosphamide, and bendamustine or with nucleoside analogs such fludarabine and cladribine;
- **Corticosteroids**, including prednisone and dexamethasone;
- **Biologic therapy** with monoclonal antibodies such as rituximab and ofatumumab;
- **Immunomodulatory drugs**, including thalidomide and lenalidomide;
- **Proteasome inhibitors** such as bortezomib and carfilzomib;
- **Targeted therapies** to the B-cell signaling pathways, including Imbruvica and everolimus;
• **Supportive therapy** such as transfusions or growth factors to boost red blood cells, white blood cells, and platelets;

• **Surgical or other procedures**, including splenectomy (surgical removal of the spleen), plasmapheresis to remove IgM, targeted radiation to reduce the size of lymph nodes, and stem cell transplantation.

When treatment is being considered, a WM patient may want to ask his or her local hematologist-oncologist to consult with a WM expert at a major medical center for a second opinion about the necessity for treatment and the various treatment options available. This can be very helpful because few hematologist-oncologists have a great deal of experience with a rare disease like WM.

Many of the older, established treatments are still appropriate for WM patients. While Imbruvica, an oral drug that targets the Bruton’s tyrosine kinase (BTK) pathway in B-cell growth and development, is a very important step forward in treatment, it is not a cure for WM and not everyone responds to it.

Treatment can usually be administered in an outpatient setting or at home and may be oral, by intramuscular or subcutaneous injection, or by intravenous therapy. Some treatments require that certain medications be taken the day before or the day of treatment in order to minimize associated side effects. Traditionally, treatment has been done in cycles that may take several weeks to months, depending on the course of therapy chosen. It is not unusual to have a round of therapy and then wait a week or a month before another round of treatment. Some of the newer oral therapies such as Imbruvica require daily dosing instead, until relapse or significant toxicities develop.

A relapse or recurrence after treatment occurs when laboratory values and physical signs and symptoms begin to trend in a deteriorating direction. These signs and symptoms may be quite similar to those that led to initial treatment. At this point, patients and their hematologist-oncologists are confronted with choosing the next appropriate course of action, be it continued periodic monitoring or re-treatment.

The severity of symptoms, overall health condition, quality of life, and candidacy for future stem cell transplantation will factor into the decision of when to begin re-treatment. The question becomes: Which treatment to choose? In general, if a patient has had good results with a prior therapy that led to a significant period of response (1-2 years or more), then a repeat treatment with the same therapy may be appropriate. If a prior therapy was not very effective or the response period was short, a different type of therapy is indicated.

The IWMF also encourages patients to consider participating in clinical trials if they are thinking about treatment. Information on currently available clinical trials can be searched for on the US government website [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

Most treatments for WM come with side effects, which can include one or more of the following: nausea or vomiting, constipation, diarrhea, low blood counts, hair loss, fatigue, infusion reactions, increased risk of infections, and neuropathy. Patients in treatment should ask for written information on potential side effects and how to manage them. There are supportive therapies to help manage many of these side effects. Patients should discuss
with their health care team any changes in symptoms or any possible side effects they are experiencing, even if they are not sure a problem is related to treatment.

**Recent developments**

Research into the genetics of WM made a major leap forward in 2011 with the discovery of a single mutation in a gene called MYD88 at a prevalence rate of 90% or more in WM patients. This was the first time that the entire genome, or complete set of DNA, of patients with WM was sequenced, with the goal to determine which genes were present in the cancer cells of these patients that were not seen in their normal cells. The same study also reported that the MYD88 mutation, designated MYD88 L265P, was not nearly as prevalent in most other types of lymphoma or in multiple myeloma. Subsequent follow-up studies by WM investigators around the world have validated these findings.

Although we do not yet know the exact role that the MYD88 mutation plays in the development and progression of WM, researchers are continuing to study the mutation’s effects on complex downstream cellular pathways and how these pathways might in turn promote the growth and proliferation of WM cells. The US National Comprehensive Cancer Network (NCCN) recently updated its guidelines for WM to include AS-PCR testing for the presence of MYD88 L265P in the bone marrow cells of suspected patients and has characterized the test as essential for the diagnosis of WM.

Several other genetic mutations appear to be fairly common in WM patients, although not to the extent of the MYD88 L265P mutation. One such group of mutations occurs in the gene CXCR4 at a prevalence rate of about 30%. Studies suggest that such mutations cause significant tumor proliferation and spread to extramedullary organs (outside the bone marrow), thereby leading to disease progression and a less favorable prognosis.

The IWMF has played a major role in funding these recent genetic studies and intends to expand its research role in the near future. Since its incorporation in 1998, the IWMF has raised over $8.1 million USD for research and has built strong relationships with many institutions in the US, Canada, and abroad. All potential IWMF-funded research projects are reviewed by our prestigious Scientific Advisory Committee (SAC), chaired by Dr. Robert A. Kyle, MD, of the Mayo Clinic. This Committee provides comments and feedback to researchers so that their proposals can be refined and recommends the most promising research projects to the IWMF Research Committee and the IWMF Board of Trustees for funding consideration.

In 2014, the Foundation decided that the time was right to update its research strategy and enlist the cooperation of many of the major players in the WM research community. To this end, the IWMF partnered with the Leukemia & Lymphoma Society (LLS) to sponsor a Strategic Research Roadmap Conference in May 2015. The Roadmap Conference was attended by a number of WM researchers and resulted in the identification of four key priority areas where concentrated research is needed:

- **Genomics and Epigenomics** – The genetic basis for unmutated MYD88 (also called wild-type) disease remains unknown, and one important priority should be the use of improved laboratory genetic sequencing techniques to identify this basis. The epigenome consists of chemical
compounds and proteins that can attach to DNA and turn genes on or off, thereby controlling the production of proteins in cells. The epigenome has undergone extensive study in other B-cell malignancies. A comprehensive analysis of the epigenome of WM cells whose MYD88 and CXCR4 status are known will provide insights into potential therapeutic targets.

- **Signaling** - Studies are needed to identify signaling pathways and downstream proteins associated with mutated MYD88 and mutated CXCR4 in order to advance future WM treatments;

- **Immunotherapy** – The mechanism whereby a WM patient’s own immune system can be manipulated or triggered to recognize and subsequently attack the offending WM cells remains unknown. Research to understand the biology of the immune response in WM is vitally important;

- **Bone marrow/tumor microenvironment** – Focused research is needed into the role of the bone marrow and tumor microenvironment (the “neighborhood” around WM cells) in supporting malignant cell growth in WM. Studies are required to better characterize the components of the microenvironment, as well as its contribution to disease progression and resistance to treatment.

Current plans under the IWMF-LLS Strategic Research Roadmap Initiative are to review, approve, and fund proposed projects that address these key areas.

**Survivorship**

Advances in the treatment of WM have led to an improved life expectancy for people living with the disease. Some patients are experiencing extended responses from treatment, and others continue to manage the disease with ongoing therapies. Living longer with WM presents new challenges...managing long-term treatment-related side effects (fatigue, increased risk of infections, neuropathy, chemo brain, etc.) and coping with the emotional, social, employment, and financial issues that may persist.

Maximizing quality of life throughout the WM journey is key to overall well-being and requires active participation by the WM patient/caregiver and health care professionals. Essential areas to target may include healthy lifestyles (nutrition, physical activity, relaxation, etc.), support system, counseling, pain management, and use of financial/employment resources. Ideally, the goal is to thrive, not just survive, within the scope of each person’s unique WM experience.

**About the IWMF**

The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and volunteer-led, nonprofit 501(c)(3) organization with an important mission: To offer mutual support and encouragement to the Waldenstrom’s macroglobulinemia community and others with an interest in the disease; to provide information and educational programs that address patients’ concerns; and to promote and support research leading to better treatments and ultimately, a cure.

The IWMF and its international Affiliates provide a wide variety of services to help patients and their caregivers understand and cope with WM. These include a network of Support Groups, our Internet
About Waldenstrom’s Macroglobulinemia Fact Sheet

group discussion forums, our volunteer-based telephone and email LIFELINE, and our quarterly newsletter, the Torch.

We offer a variety of publications, including Information Packets (Info Paks) for newly diagnosed patients. Designed to provide very readable, up to date information about WM they also describe the benefits of membership in the IWMF. Info Paks are available through our website [www.iwmf.com/about-wm/newly-diagnosed](http://www.iwmf.com/about-wm/newly-diagnosed).

We encourage WM patients and caregivers to attend our annual Educational Forum, which provides a unique opportunity to hear about the latest research and treatments in WM. It’s also a great way to network with other patients. The Educational Forum happens every spring and rotates to various regions around the US. Several of our Affiliates also hold periodic country-specific educational forums.

More information about Waldenstrom’s macroglobulinemia and these and other services offered by the IWMF can be found on our website, [www.iwmf.com](http://www.iwmf.com). Our international Affiliates and their websites/contact information can be found at [www.iwmf.com/about-us/international-affiliates](http://www.iwmf.com/about-us/international-affiliates).

The IWMF relies on donations to continue its mission, and we welcome your support. The Foundation maintains a Business Office at 6144 Clark Center, Ave., Sarasota, FL 34238. The Office can be contacted by phone at 941-927-4963, by fax at 941-927-4467, or by email at [info@iwmf.com](mailto:info@iwmf.com).

Acknowledgment

The IWMF gratefully acknowledges Dr. Robert A. Kyle, MD, of the Mayo Clinic in Rochester, MN, for his medical review of this publication.

---

The information presented here is intended for education purposes only. It is not meant to be a substitute for professional medical advice. Patients should use the information provided in full consultation with, and under the care of, a professional medical specialist with experience in the treatment of WM. We discourage the use by a patient of any information contained here without disclosure to his or her medical specialist.

Copyright The International Waldenstrom’s Macroglobulinemia Foundation December 2015